Last reviewed · How we verify

Topical TXA

Massachusetts General Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Topical TXA is a Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved. Also known as: Topical Tranexamic acid, Topical TXA through drain, TXA.

Tranexamic acid is being studied in various clinical trials for conditions such as femoral neck fracture, spine surgery, back pain, pulmonary embolism, and deep vein thrombosis. Topical tranexamic acid administration is being investigated as a treatment option in these trials, although the exact mechanism of action is currently unknown.

At a glance

Generic nameTopical TXA
Also known asTopical Tranexamic acid, Topical TXA through drain, TXA
SponsorMassachusetts General Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topical TXA

What is Topical TXA?

Topical TXA is a Small molecule drug developed by Massachusetts General Hospital.

Who makes Topical TXA?

Topical TXA is developed and marketed by Massachusetts General Hospital (see full Massachusetts General Hospital pipeline at /company/massachusetts-general-hospital).

Is Topical TXA also known as anything else?

Topical TXA is also known as Topical Tranexamic acid, Topical TXA through drain, TXA.

What development phase is Topical TXA in?

Topical TXA is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing